Evidence map›Paper›PMID 35572130›Full record

ArticleFrontiers in aging neuroscience2022

Bioinformatics Analysis of Publicly Available Single-Nuclei Transcriptomics Alzheimer's Disease Datasets Reveals

Stella A Belonwu, Yaqiao Li, Daniel G Bunis, Arjun Arkal Rao, Caroline Warly Solsberg, Tomiko Oskotsky, Alice L Taubes, Brian Grone, Kelly A Zalocusky, Gabriela K Fragiadakis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Stella A BelonwuBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Yaqiao LiBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Daniel G BunisBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Arjun Arkal RaoCoLabs, University of California, San Francisco, San Francisco, CA, United States.
Caroline Warly SolsbergBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Tomiko OskotskyBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Alice L TaubesBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
Brian GroneGladstone Institute of Neurological Disease, San Francisco, CA, United States.
Kelly A ZalocuskyGladstone Institute of Neurological Disease, San Francisco, CA, United States.
Gabriela K FragiadakisCoLabs, University of California, San Francisco, San Francisco, CA, United States.
Yadong HuangDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Marina SirotaBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.
University of California, San Francisco · USGladstone Institutes · USUniversity Memory and Aging Center · US

Funding

ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's DiseaseR01AG057683 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG, SIROTA, MARINA · 2017 to 2021
$4.3M
An Integrative Multi-Omics Approach to Elucidate Sex-Specific Differences in Alzheimers DiseaseR01AG060393 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SIROTA, MARINA · 2018 to 2022
$4.1M
NIA NIH HHS R01 AG057683NIA NIH HHS R01 AG060393
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a complex neurodegenerative disease that gravely affects patients and imposes an immense burden on caregivers. Apolipoprotein E4 (APOE4) has been identified as the most common genetic risk factor for AD, yet the molecular mechanisms connecting APOE4 to AD are not well understood. Past transcriptomic analyses in AD have revealed

Indexed as

Alzheimer’s diseaseAPOEdifferential expressionnetwork enrichmentRNA-sequencingsingle-cell

Identifiers

PMID35572130
PMCPMC9093608
OpenAlexW4285745086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.